Trial Profile
A Randomized Double-Blind, Double-Dummy, Crossover Study to Evaluate the Efficacy and Safety of Prolonged-Release Melatonin and Clonazepam in Patients With Rapid Eye Movement (REM) Sleep Behavior Disorder in Parkinson Disease
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Dec 2019
Price :
$35
*
At a glance
- Drugs Clonazepam (Primary) ; Melatonin (Primary)
- Indications Parkinson's disease; REM-sleep-behavior-disorder
- Focus Therapeutic Use
- Sponsors Kuhnil Pharmaceutical Company
- 10 Jun 2016 New trial record